Original Coverage & Source Attribution: crisprmedicinenews.com
CRISPR reached the clinic as a licensed medicine in 2023, and in 2025 a bespoke base editor corrected a rare disease in a single infant. Wins such as these rest on three decades of hard-won lessons in managing genotoxic risk.
This webinar traces that path: from the oncogenic events that halted early viral vector trials, to the translocations, off-target edits, and modality-specific liabilities of CRISPR-based applications. We’ll connect each lesson to the analytical methods they inspired and to evolving FDA guidance, including the 2024 genome editing guidance and the recent April 2026 draft on next-generation sequencing.
You’ll learn how past clinical findings reshaped therapy design and safety assays, the key genome safety risks across today’s editing platforms, and what the FDA now expects in a genome safety assessment package. Join us to see how history is shaping the future of gene editing.
Speaker: Robert Policastro, PhD, Manager, Bioinformatics at MaxCyte, Inc.
Register here.
Tuesday, November 3rd at 11:00am EST / 5:00pm CET
Genome Safety Webinar Series: Regulatory Expectations, Practical Workflows, and Expert Insights
Supported by MaxCyte®
